Reconstruction in Advanced Head and Neck Cancer

In this presentation, Dr. N. Eddie Liou discusses current recommendations and techniques for patients with head and neck cancer requiring reconstructive treatment, especially those with locally advanced disease.

This Hematology and Oncology Grand Rounds session took place on Friday, September 24, 2021 at 12:00 P.M.

CME Information

CME Credit Available

You may claim CME credit after watching this activity.

You will be redirected to an outside site when claiming credit and may be asked to register or log in.

Needs Statement

Hematologist-oncologists, radiation oncologists, surgeons, other medical specialists, basic and translational research scientists, residents, fellows, and medical students need to be regularly updated on advances in the diagnosis and management of patients with hematologic disorders and related malignancies. The series aims to broaden the knowledge base of learners in these topic areas and improve their competencies to enhance the patient care experience and outcomes.

Objectives

At the conclusion of the session, the participants should be able to:

  • Interpret the historical evolution of reconstruction after surgical resection of head and neck cancer.
  • Identify patients who would benefit from microvascular free-tissue transfer after surgical ablation.
  • Analyze and determine the benefit of free-flap reconstruction in patients requiring adjuvant therapy.
  • Evaluate the issues that may affect neoadjuvant or adjuvant therapy and timing of surgical treatment in patients requiring free-flap reconstruction.

Target Audience

  • Physicians
  • Medical Students
  • Fellows
  • Residents
  • Other Health Professionals

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Director

  1. Tannaz Armaghany, M.D.

    Tannaz Armaghany, M.D.

    Assistant Professor
    Baylor College of Medicine

Term of Approval

August 1, 2021 through August 31, 2023. Original release date: August 1, 2021

Disclosure Policy

The Office of Continuing Medical Education (OCME) makes every effort to develop CME activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial SupportSM, Baylor College of Medicine (BCM) has implemented a mechanism requiring everyone in a position to control the content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships: 1) at the time of the activity or within 12 months prior; and 2) of their spouses/partners.

Baylor College of Medicine does not view the existence of interests or relationships with commercial entities as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

If at any time during this activity you feel that there has been commercial or promotional bias, please inform us by using the commercial bias comments box in the evaluation form. Please answer the questions about balance in the CME activity evaluation candidly.

Disclosures

The following individual(s) has/have reported financial or other relationship(s) with commercial entities whose products/services may relate to the educational content of this activity:

Presenter

  1. N. Eddie Liou, M.D., F.A.C.S.

    N. Eddie Liou, M.D., F.A.C.S.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

Program Director

  1. Tannaz Armaghany, M.D.

    Tannaz Armaghany, M.D.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

Planning Committee Members

  1. Tannaz Armaghany, M.D.

    Tannaz Armaghany, M.D.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

  2. Salma Kaochar, M.D. Placeholder Image

    Salma Kaochar, M.D.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:
    • Research Support: FGH Biotech; Systems Oncology
    • Consultancy: FGH Biotech; Systems Oncology
  3. Tamer Khashab, M.D.

    Tamer Khashab, M.D.

    Hematology & Oncology Fellow
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

  4. Daniel Y. Wang, M.D.

    Daniel Y. Wang, M.D.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:
    • Advisory Committee Membership: Regeneron; Sanofi-Genzyme
    • Honorarium Recipient: Pri-Med

Contributor

  1. N. Eddie Liou, M.D., F.A.C.S.

    N. Eddie Liou, M.D., F.A.C.S.

    Assistant Professor
    Baylor College of Medicine

    Disclosure:

    Nothing to disclose.

CME Credit Available

You may claim CME credit after watching this activity.

View the CME Information Claim CME

You will be redirected to an outside site when claiming credit and may be asked to register or log in.

Presenter:

  1. N. Eddie Liou, M.D., F.A.C.S.

    N. Eddie Liou, M.D., F.A.C.S.

    Assistant Professor Baylor College of Medicine